Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2006-2017

  Chaturvedi, Nagendra K ^a   Rajule, Rajkumar N ^b   Shukla, Ashima ^a   Radhakrishnan, Prakash ^b   Todd, Gordon L ^a   Natarajan, Amarnath ^b   Vose, Julie M ^a   Joshi, Shantaram S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 197; ALPHA TUBULIN; BETA ACTIN; CYCLIN D1; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; PROTEIN MCL 1; QUINOXALINE DERIVATIVE; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCID MOUSE; SURVIVAL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; LYMPHOMA, MANTLE-CELL; MICE; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PHENYLUREA COMPOUNDS; QUINOXALINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885663932     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0239     Document Type: Article

References (44)

1. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following highdose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102: 749-55.
2. Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004;15: 283-90.
3. Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29: 1803-11.
4. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 2005;17: 425-31.
5. Williams ME, Dreyling M, Winter J, Muneer S, Leonard JP. Management of mantle cell lymphoma: key challenges and next steps. Clin Lymphoma Myeloma Leuk 2010;10: 336-46.
6. Diefenbach CS, O'Connor OA. Mantle cell lymphoma in relapse: the role of emerging new drugs. Curr Opin Oncol 2010;22: 419-23.
7. Jacobsen E, Freedman A. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004;16: 106-13.
8. Leonard JP, Williams ME, Goy A, Grant S, Pfreundschuh M, Rosen ST, et al. Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma 2009;9: 267-77.
9. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117: 26-38.
10. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006;107: 4540-8.
11. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109: 2700-7.
12. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003;63: 8226-32.
13. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171: 88-95.
14. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005;70: 700-13.
15. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 2008;7:40.
16. Ahrens AK, Chaturvedi NK, Nordgren TM, Dave BJ, Joshi SS. Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites. Leuk Lymphoma 2012;53: 2269-78.
17. Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N, et al. Expression of the NF-kappaB targets BCL2 and BIRC5/survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005;206: 123-34.
18. Zak Z, Gelebart P, Lai R. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting theTNFalpha/NF-kappaB signaling axis. Leukemia 2010;24: 1476-86.
19. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A, et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008;111: 5142-51.
20. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11: 32-50.
21. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441: 431-6.
22. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13: 738-47.
23. Israel A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2010;2:a000158.
24. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18: 2195-224.
25. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132: 344-62.
26. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37: 19-24.
27. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007;130: 440-55.
28. Radharkrishnan P, Bryant VC, Blowers EC, Rajule R, Gautham N, Anwar MM, et al. Targeting the NF-kB and mTOR pathways with a quinoxaline urea analog that inhibits IKKb for pancreas cancer therapy. Clin Cancer Res 2013;19: 2025-35.
29. Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007;178: 1923-30.
30. Lopez-Guerra M, Roue G, Perez-Galan P, Alonso R, Villamor N, Montserrat E, et al. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clin Cancer Res 2009;15: 2767-76.
31. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012;246: 379-400.
32. Xia Y, Yeddula N, Leblanc M, Ke E, Zhang Y, Oldfield E, et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol 2012;14: 257-65.
33. Greten FR, Arkan MC, Bollrath J, Hsu JC, Goode J, Miething C, et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007;130: 918-31.
34. Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 2010;14: 347-61.
35. Rajule R, Bryant VC, Lopez H, Luo X, Natarajan A. Perturbing prosurvival proteins using quinoxaline derivatives: a structure-activity relationship study. Bioorg Med Chem 2012;20: 2227-34.
36. Chen Q, Bryant VC, Lopez H, Kelly DL, Luo X, Natarajan A. 2,3- Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure- activity relationship study. Bioorg Med Chem Lett 2011;21: 1929-32.
37. Bryant VC, Kishore Kumar GD, Nyong AM, Natarajan A. Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs. Bioorg Med Chem Lett 2012;22: 245-8.
38. Hegde GV, Nordgren TM, Munger CM, Mittal AK, Bierman PJ, Weisenburger DD, et al. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling. Int J Cancer 2012;131: 2951-60.
39. Gautam N, Bathena SP, Chen Q, Natarajan A, Alnouti Y. Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-kB inhibitor in mice and rats by LC-MS/MS. Biomed Chromatogr 2013;27: 900-9.
40. Hegde GV, Munger CM, Emanuel K, Joshi AD, Greiner TC, Weisenburger DD, et al. Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma. Mol Cancer Ther 2008;7: 1450-60.
41. Cecconi D, Zamo A, Bianchi E, Parisi A, Barbi S, Milli A, et al. Signal transduction pathways of mantle cell lymphoma: a phosphoproteomebased study. Proteomics 2008;8: 4495-506.
42. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006;169: 2171-80.
43. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7: 750-62.
44. Guo R, Chang L, Liu Z, Li AX, Huang Q, Ann DK, et al. Canonical nuclear factor kB pathway links tumorigenesis of synchronous mantle-cell lymphoma, clear-cell renal-cell carcinoma, and GI stromal tumor. J Clin Oncol 2011;29: 257-61.